Cardlytics, Inc. cash flow to debt ratio of 4.31% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Cardlytics, Inc.'s free cash flow has increased -131.33% from $-28.12M last year to $8.81M, signaling increasing performance

Cardlytics, Inc.'s debt to equity ratio is -52.47, signaling that the company spent its equity and risk bankruptcy.

Cardlytics, Inc.'s debt to equity ratio is -52.47, signaling that the company spent its equity and risk bankruptcy.

Cardlytics, Inc. has negative EBITDA, making leverage ratio unreliable

Cardlytics, Inc.'s interest coverage ratio is -8.51, which means that the company struggles to meet interest obligations, signaling financial risk.

Cardlytics, Inc.'s profit margin has increased (-32.33%) in the last year from -68.02% to -46.03%, signaling increasing performance

Cardlytics, Inc.'s short-term assets of $137.28M exceed its short-term liabilities of $78.39M

Cardlytics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Cardlytics, Inc.'s return on equity of -870.86%, is lower than 15.00%, indicating bad performance

Cardlytics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Cardlytics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Cardlytics, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Cardlytics, Inc. has a free cash flow yield of 35.95%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Cardlytics, Inc.'s yearly earnings has increased -45.33% since last year from $-189.30M to $-103.49M, signaling increasing performance

Cardlytics, Inc.'s yearly revenue has decreased -16.18% since last year from $278.30M to $233.27M, signaling decreasing performance

ROIC -45.63% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Cardlytics, Inc.'s 3-year revenue CAGR of -7.89% is negative, indicating declining revenue over the past 3 years

Cardlytics, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Cardlytics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Cardlytics, Inc. has insufficient data to evaluate this check.

Cardlytics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cardlytics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Cardlytics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Cardlytics, Inc. is overvalued relative to its fair value price of -279.74 based on Earnings Fair Value model

Cardlytics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cardlytics, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Cardlytics, Inc. has a price-to-sales ratio of 0.11x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue